Roche Does Not Feel Eylea Biosimilars Will Change The Status Quo

50/50 Dynamic Of Biosimilars And Brands Expected, No Step Throughs Seen Currently

25 Oct 2024

Roche’s 2022-launched Vabysmo took no time at all to reach the coveted $1bn in sales, and the originator is continuing to feel optimistic about the newer-generation VEGF brand’s prospects, even as Amgen readies the launch of the first US biosimilar to Eylea.

Roche is not spooked by the prospect of earlier-than-anticipated biosimilar competition to Eylea (aflibercept), as it continues to back its next-generation product for wet age-related macular degeneration – the dual VEGF/Ang-2 inhibitor Vabysmo (faricimab-svoa), which has quickly soared to blockbuster status.

Earlier this week, Amgen told Generics Bulletin that it was launching the first US biosimilar to Regeneron’s earlier VEGF...